# A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

> **NCT00353522** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 135 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** dalcetrapib

## Key facts

- **NCT ID:** NCT00353522
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00353522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00353522, "A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00353522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*